Can anything shut down the Gold rally?
VANCOUVER - Robert Cross, a significant shareholder in Ondine Biomedical Inc., has increased his voting rights in the company to 7.29%, according to a regulatory filing disclosed Thursday.
The notification of major holdings revealed that Cross now controls 37,772,652 voting rights in the Canadian-based biomedical company. The threshold was crossed on Wednesday, September 3, 2025.
According to the filing, Cross holds his stake primarily through Paloduro Investments, which accounts for approximately 6.27% of the total voting rights in Ondine Biomedical.
The disclosure, made in accordance with regulatory requirements for major shareholders, indicates the change resulted from "an event changing the breakdown of voting rights" rather than a new acquisition or disposal of shares.
Cross, who is based in Vancouver, Canada, made the notification to comply with transparency rules that require investors to disclose when their holdings cross certain thresholds.
Ondine Biomedical Inc. is listed with the ISIN code CA68234M2058. The company did not provide additional commentary on the change in shareholding structure in the regulatory announcement.
The information was submitted through RNS, the news service of the London Stock Exchange, as part of standard market disclosure requirements for significant changes in company ownership.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.